Zai Lab and Amgen Collaborate on Combination Therapy for Lung Cancer
Zai Lab (ZLAB) and Amgen (AMGN) have entered into a global clinical trial collaboration to evaluate a combination therapy for extensive-stage small cell lung cancer (ES-SCLC). The study will combine Zai Lab’s zocilurtatug pelitecan with Amgen’s IMDELLTRA, both targeting DLL3. The partnership aims to improve clinical outcomes for a patient population with a median survival of 12 months.
Topics: Clinical Trials Drug Development Lung Cancer Therapy Pharmaceutical Research